Childhood psoriasis was found to be significantly associated with environmental tobacco smoke exposure, whereas intrauterine smoking exposure was not associated with an increased risk in pediatric populations.
Environmental exposure to tobacco smoke may increase the risk of psoriasis by more than 2-fold in children, according to study findings published recently in Pediatric Dermatology.
Despite one-third of cases of psoriasis beginning in childhood–with prevalence estimated to be 128 cases per 100,000 children–researchers note that there remains limited evidence on what risk factors may increase risk of pediatric onset.
“To date, infections, family history of psoriasis, stressors, and obesity have been related to childhood psoriasis. The effects of intrauterine or childhood tobacco smoke exposure and its relationship to childhood psoriasis have previously been reported in 2 studies,” they said.
Seeking to better understand the association between intrauterine, infantile, and childhood tobacco smoke exposure and incidence of pediatric psoriasis, researchers conducted a case-control study of patients younger than 18 years of age seen in the Turkish Ankara University Dermatology Department from June 2016 to March 2020 who had a diagnosis of psoriasis as a child (n = 130; mean [SD] age, 10.19 [3.92] years; 50.8% male).
Patients with a diagnosis of childhood psoriasis were compared with age- and sex-matched controls (n = 390), in which use of 1 or more cigarettes per day for at least 1 month during pregnancy was considered intrauterine smoke exposure for children and exposure to tobacco smoke in childhood was defined as the use of 1 or more cigarettes per day for at least 1 year by at least 1 permanent member of the household.
“From the pool of children managed in our clinic during the study period, 3 sex- and age-matched children with non-inflammatory skin diseases such as tinea, candida, molluscum contagiosum, or verruca vulgaris were included in the study as controls for each child with psoriasis,” explained researchers.
For the childhood psoriasis cohort, mean [SD] age of onset of psoriasis was not found to differ between males (7.61 [4.30]) and females (7.30 [3.62]; P = .876). Notably, the rate of having a family history of psoriasis was significantly higher in the intervention group compared with the control group (27.7% vs. 4.9%) (P < .001), as was reported incidence of overweight or obesity (P = .002), intrauterine tobacco smoke exposure (11.5% vs. 5.9%), and environmental tobacco smoke exposure at home (56.9% vs. 34.6%).
After conducting a multivariate conditional logistic regression analysis that adjusted for intrauterine smoking exposure, family history of psoriasis, and obesity, environmental tobacco exposure was found to be significantly associated with incidence of childhood psoriasis (OR, 2.23; 95% CI, 1.39-3.58).
Conversely, no significant relationship was found between intrauterine smoking exposure and incidence of childhood psoriasis (OR, 1.61; 95% CI, 0.75-3.43; P = .212).
Speaking on the study findings, researchers acknowledged several limitations, including the lack of comparison with the general Turkish population, the relatively low number of cases, and the lack of information regarding parental socioeconomic status.
“Further studies investigating the relationship between childhood psoriasis and degree of smoking exposure, and the timing of the exposure in large cohorts that have been diagnosed by expert dermatologists are needed to elucidate such a relationship,” they concluded.
Reference
Atak MF, Kundakci N, Farabi B. Link between childhood tobacco exposure and childhood psoriasis: A case-control study. Pediatr Dermatol. Published online December 17, 2021. doi:10.1111/pde.14896
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More